06660 艾美疫苗
按盘价 
7.400 +0.060 (+0.817%) 盈利能力分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 资产回报率 (%) | -16.124% | -3.772% | -10.858% | 9.931% | 3.979% |
| 股东资金回报率 (%) | -30.245% | -6.487% | -16.665% | 15.291% | 7.627% |
| 资本运用回报率 (%) | -27.918% | -4.823% | -10.654% | 10.663% | 6.672% |
边际利润分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 毛利率 (%) | 75.877% | 81.297% | 82.458% | 82.669% | 77.008% |
| 未计利息、税项、折旧及摊销前利润率 (%) | -173.716% | -19.993% | -29.455% | 37.805% | 28.720% |
| 税前边际利润率 (%) | -191.217% | -34.347% | -38.640% | 29.664% | 16.473% |
| 纯利率 (%) | -109.561% | -25.283% | -44.122% | 23.156% | 12.337% |
变现能力分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 流动比率 (X) | 0.954 X | 1.133 X | 1.502 X | 2.156 X | 1.130 X |
| 速动比率 (X) | 0.758 X | 0.909 X | 1.268 X | 1.933 X | 0.938 X |
财务杠杆分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 总负债 / 总资产比率 (%) | 46.439% | 33.967% | 29.397% | 27.012% | 45.162% |
| 总债项 / 总资产比率 (%) | 24.726% | 15.758% | 8.058% | 5.014% | 10.656% |
| 净债项 / 总资产比率 (%) | 16.696% | 8.602% | 0.046% | -18.511% | -0.142% |
| 总债项 / 股东资金比率 (%) | 49.293% | 28.198% | 13.294% | 6.869% | 20.427% |
| 长期债项 / 股东资金比率 (%) | 15.630% | 7.432% | 4.623% | 1.364% | 3.307% |
| 净债项 / 股东资金比率 (%) | 33.284% | 15.392% | 0.075% | -25.362% | -0.273% |
| 净现金 / (债项) ($) | (12.12亿) | (7.63亿) | (3.69百万) | 8.68亿 | 4.20百万 |
| 每股净现金 / (债项) ($) | (1.001) | (0.630) | -- | -- | -- |
| 总债项 / 资本运用比率 (%) | 38.532% | 21.109% | 10.003% | 6.608% | 17.869% |
| 利息盈利率 (X) | N/A | N/A | N/A | 31.868 X | 15.540 X |
营运效率分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 存货周转率日数 (日) | 646.405日 | 673.245日 | 410.887日 | 309.562日 | 381.703日 |
| 应收贸易帐周转率日数 (日) | 316.239日 | 305.532日 | 224.737日 | 146.482日 | 170.615日 |
| 应付贸易帐周转率日数 (日) | 20.585日 | 18.097日 | 10.430日 | 9.013日 | 16.464日 |
| 备注： | 实时报价更新时间为27/11/2024 17:59 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) () | RMB -139,254,000 |
| 增长率 | -44.380% |
| 每股盈利/(亏损) | RMB -0.110 |
| 每股账面资产净值 (¥) | RMB 2.893 |